'

GET ACTIVE

Encourage others to start talking and gain control of their bladder health!  We've made it simple for you to share National Bladder Health Week news, resources, tips and tools with your friends, family and healthcare providers.  We have a variety of  simple activities you can choose from to promote awareness of bladder health.  They are cut and paste one of the sample newsletter or emails below.

28 Society Street
Charleston, SC, 29401
United States

800-252-3337

NAFC is a non-profit offering resources for #incontinence, #bladderleakage, bedwetting, OAB, SUI, nocturia, neurogenic bladder, and pelvic floor disorders.

INCONTINENCE STORIES FROM EXPERTS AND REAL PEOPLE | BHEALTH

Log in daily to learn tips about #incontinence, #bladder leakage, overcoming symptoms, and first hand accounts from experts and patients.

 

LEADERSHIP 301 Trial For People With Interstitial Cystitis/Bladder Pain Syndrome

Sarah Jenkins

Interstitial Cystitis/Bladder Pain Syndrome Clinical Study Recruitment

Purpose

The purpose of the LEADERSHIP 301 Trial is to learn if an investigational drug, AQX-1125, may reduce the bladder pain of interstitial cystitis/bladder pain syndrome (IC/BPS) and relieve other symptoms such as urinary urgency and frequency. The study drug is a new type of medication that may help reduce inflammation in the bladder.

An earlier clinical study in women with IC/BPS showed that the women who took the study drug every day for 6 weeks experienced reduced bladder pain and improved symptoms compared to those who took placebo.

Eligibility

You may qualify if you:

  • Are between the ages of 18 and 80
  • Have been diagnosed with interstitial cystitis/bladder pain syndrome (IC/BPS) for at least 3 months
  • Have consistently experienced moderate to severe bladder pain, urinary urgency and/or urinary frequency

What will Happen During the Study

As a study participant, you will have regular contact with our study team who will monitor your health closely. There will be11-12 visits during the study, which will last 16 months.  There will be a 12-week treatment period and a 40-week extension.

During the treatment period there will be a 1 in 3 chance you will receive placebo. After completing the treatment period, you will be randomized into an extension period where all patients receive active study drug.

Research Study Title

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period

Sponsor

Aquinox Pharmaceuticals (Canada) Inc.

For additional study information:

clinicaltrials.gov study listing

www.LEADERSHIP301.com